Reata Pharmaceuticals Inc (RETA) Expected to Post Earnings of -$0.88 Per Share

Equities research analysts expect Reata Pharmaceuticals Inc (NASDAQ:RETA) to report ($0.88) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Reata Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.04) and the highest is ($0.68). Reata Pharmaceuticals posted earnings of ($0.64) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 37.5%. The firm is scheduled to report its next earnings report on Friday, March 1st.

On average, analysts expect that Reata Pharmaceuticals will report full-year earnings of ($2.61) per share for the current financial year, with EPS estimates ranging from ($3.04) to ($2.26). For the next year, analysts expect that the business will report earnings of ($3.49) per share, with EPS estimates ranging from ($4.19) to ($3.15). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Reata Pharmaceuticals.

Reata Pharmaceuticals (NASDAQ:RETA) last announced its earnings results on Wednesday, November 7th. The company reported ($1.07) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.79) by ($0.28). The company had revenue of $5.18 million during the quarter, compared to analyst estimates of $9.50 million.

Several research analysts recently weighed in on RETA shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 target price on shares of Reata Pharmaceuticals in a research note on Monday, October 1st. BidaskClub downgraded Reata Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $133.00 target price on shares of Reata Pharmaceuticals in a report on Wednesday, September 26th. ValuEngine raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, July 18th. Finally, Zacks Investment Research raised Reata Pharmaceuticals from a “hold” rating to a “buy” rating and set a $43.00 target price for the company in a report on Friday, July 13th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $100.33.

Shares of RETA stock opened at $65.78 on Wednesday. Reata Pharmaceuticals has a fifty-two week low of $19.31 and a fifty-two week high of $99.50.

In other news, insider Keith Wayne Ward sold 14,250 shares of the company’s stock in a transaction on Tuesday, October 23rd. The stock was sold at an average price of $57.08, for a total transaction of $813,390.00. Following the completion of the sale, the insider now directly owns 14,250 shares of the company’s stock, valued at $813,390. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 23,750 shares of company stock valued at $1,414,028. 31.69% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in RETA. Lee Financial Co purchased a new stake in shares of Reata Pharmaceuticals during the third quarter valued at $128,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Reata Pharmaceuticals during the second quarter valued at $154,000. First Mercantile Trust Co. purchased a new stake in shares of Reata Pharmaceuticals during the third quarter valued at $167,000. Metropolitan Life Insurance Co. NY lifted its stake in Reata Pharmaceuticals by 53.2% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 5,460 shares of the company’s stock worth $191,000 after acquiring an additional 1,897 shares in the last quarter. Finally, Voya Investment Management LLC purchased a new stake in Reata Pharmaceuticals in the 2nd quarter worth about $213,000. 40.73% of the stock is owned by institutional investors and hedge funds.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases with therapies by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome; and for a form of pulmonary arterial hypertension associated with connective tissue disease.

Read More: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Reata Pharmaceuticals (RETA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply